2-METHYL-3-(4-PYRIDIN-2-YL-PIPERAZIN-1-YL)-PROPIONIC ACID
|
- $378 - $777.32
- Product name: 2-METHYL-3-(4-PYRIDIN-2-YL-PIPERAZIN-1-YL)-PROPIONIC ACID
- CAS: 883544-42-1
- MF: C13H19N3O2
- MW: 249.31
- EINECS:
- MDL Number:MFCD07186546
- Synonyms:ASINEX-REAG BAS 13299654;AKOS BBS-00005806;2-METHYL-3-(4-PYRIDIN-2-YL-PIPERAZIN-1-YL)-PROPIONIC ACID;TIMTEC-BB SBB011927;2-Methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)propanoic acid;1-Piperazinepropanoic acid, α-methyl-4-(2-pyridinyl)-
3 prices
Selected condition：
Brand
- American Custom Chemicals Corporation
- Crysdot
- Matrix Scientific
Package
- 500MG
- 1g
- 5g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0084189
- Product description2-METHYL-3-(4-PYRIDIN-2-YL-PIPERAZIN-1-YL)-PROPIONIC ACID 95.00%
- Packaging500MG
- Price$777.32
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11034521
- Product description2-Methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)propanoicacid 97%
- Packaging5g
- Price$701
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number019835
- Product description2-Methyl-3-(4-pyridin-2-yl-piperazin-1-yl)-propionic acid
- Packaging1g
- Price$378
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| American Custom Chemicals Corporation | CHM0084189 | 2-METHYL-3-(4-PYRIDIN-2-YL-PIPERAZIN-1-YL)-PROPIONIC ACID 95.00% | 500MG | $777.32 | 2021-12-16 | Buy |
| Crysdot | CD11034521 | 2-Methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)propanoicacid 97% | 5g | $701 | 2021-12-16 | Buy |
| Matrix Scientific | 019835 | 2-Methyl-3-(4-pyridin-2-yl-piperazin-1-yl)-propionic acid | 1g | $378 | 2021-12-16 | Buy |
Properties
Boiling point :439.9±45.0 °C(Predicted)
Density :1.178±0.06 g/cm3(Predicted)
pka :3.89±0.10(Predicted)
Density :1.178±0.06 g/cm3(Predicted)
pka :3.89±0.10(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|